推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 為加強(qiáng)亳州中藥材專業(yè)市場(chǎng)上市中藥材質(zhì)量監(jiān)管，保障人民群眾用藥安全有效，樹(shù)立“中華藥都”品牌形象，日前，亳州市食品藥品監(jiān)督管理局專業(yè)市場(chǎng)分局聯(lián)合其他相關(guān)職能部門開(kāi)展中藥材質(zhì)量評(píng)價(jià)分析活動(dòng)，通過(guò)五項(xiàng)措施強(qiáng)化中藥材質(zhì)量監(jiān)管。
一是在新老中藥材專業(yè)市場(chǎng)并存期間，加強(qiáng)各部門之間的溝通交流，明確工作職責(zé)，進(jìn)一步加強(qiáng)信息共享與協(xié)作；二是加強(qiáng)中藥材專業(yè)市場(chǎng)經(jīng)營(yíng)“十不準(zhǔn)”、中藥材檢測(cè)標(biāo)準(zhǔn)以及相關(guān)法律法規(guī)的宣傳力度；三是強(qiáng)化企業(yè)的主體責(zé)任，康美（亳州）華佗國(guó)際中藥城作為第一責(zé)任人，需明確自身職責(zé)和責(zé)任；四是加強(qiáng)中藥材專業(yè)市場(chǎng)準(zhǔn)入制度，加大質(zhì)量巡查、抽樣檢驗(yàn)、行政執(zhí)法力度；五是進(jìn)一步完善中藥材專業(yè)市場(chǎng)管理長(zhǎng)效機(jī)制。
2014年以來(lái)，亳州市局積極開(kāi)展藥品藥材市場(chǎng)專項(xiàng)整治，通過(guò)各部門的聯(lián)合協(xié)作對(duì)制售假劣藥行為的嚴(yán)厲打擊，中藥材專業(yè)市場(chǎng)中藥材質(zhì)量情況與往年環(huán)比質(zhì)量呈上升趨勢(shì)，市場(chǎng)逐年凈化。
